ATE351916T1 - Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten - Google Patents

Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten

Info

Publication number
ATE351916T1
ATE351916T1 AT00969534T AT00969534T ATE351916T1 AT E351916 T1 ATE351916 T1 AT E351916T1 AT 00969534 T AT00969534 T AT 00969534T AT 00969534 T AT00969534 T AT 00969534T AT E351916 T1 ATE351916 T1 AT E351916T1
Authority
AT
Austria
Prior art keywords
recombinant cells
hiv
triplex dna
dna
vectors
Prior art date
Application number
AT00969534T
Other languages
English (en)
Inventor
Pierre Charneau
Veronique Zennou
Francoise Pflumio
Aude Sirven
Kupperschmitt Anne Dubart
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE351916T1 publication Critical patent/ATE351916T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00969534T 1999-10-12 2000-10-10 Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten ATE351916T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15838799P 1999-10-12 1999-10-12

Publications (1)

Publication Number Publication Date
ATE351916T1 true ATE351916T1 (de) 2007-02-15

Family

ID=22567880

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00969534T ATE351916T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
AT07000486T ATE531808T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07000486T ATE531808T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna

Country Status (15)

Country Link
US (7) US8093042B2 (de)
EP (2) EP1224314B1 (de)
JP (1) JP4436024B2 (de)
CN (2) CN101363029B (de)
AT (2) ATE351916T1 (de)
AU (2) AU784910B2 (de)
CA (1) CA2382832C (de)
CY (2) CY1106513T1 (de)
DE (1) DE60033045T2 (de)
DK (2) DK1792997T3 (de)
ES (2) ES2377721T3 (de)
HK (1) HK1050210B (de)
IL (3) IL148900A0 (de)
PT (2) PT1224314E (de)
WO (1) WO2001027304A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
AU784910B2 (en) 1999-10-12 2006-07-27 Centre National De La Recherche Scientifique Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US7629153B2 (en) 2001-08-02 2009-12-08 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
AU2002343458B2 (en) 2001-10-02 2008-03-20 Institut Clayton De La Recherche Methods and compositions relating to restricted expression lentiviral vectors and their applications
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1748067A1 (de) 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
EP2150618B1 (de) 2007-05-04 2017-10-11 University Health Network Il-12-immuntherapie gegen krebs
EP2385107B1 (de) 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
EP2666477A1 (de) 2012-05-23 2013-11-27 Theravectys Lentivirale Vektoren mit einem MHC-Klasse-I-Promotor
EP2643343A1 (de) 2010-11-26 2013-10-02 Institut Pasteur Identifizierung eines menschlichen gyrovirus und anwendungen
EP2592091B1 (de) 2011-11-08 2017-09-20 Institut Pasteur Polypeptide mit hoher MAST2-Affinität und deren Verwendungen
EP2788477A2 (de) 2011-12-07 2014-10-15 Institut Pasteur Identifizierung des porcinen parecho-like virus und anwendungen
WO2014016383A2 (en) 2012-07-25 2014-01-30 Theravectys Glycoproteins for pseudotyping lentivectors
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
WO2015059674A1 (en) * 2013-10-24 2015-04-30 Ospedale San Raffaele S.R.L. Method
EP3031923A1 (de) 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
WO2016128549A1 (en) 2015-02-13 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
DE102016122317A1 (de) 2015-11-24 2017-05-24 Glaxosmithkline Intellectual Property Development Limited Transientes transfektionsverfahren für retrovirale produktion
EP3211003A1 (de) 2016-02-24 2017-08-30 Institut Pasteur T-zell-rezeptoren aus dem hiv-spezifischen repertoire, mittel zu deren herstellung und therapeutische verwendung davon
EP3443001B1 (de) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
HUE055862T2 (hu) 2016-04-20 2021-12-28 Centro De Investig Energeticas Készítmények és eljárások PKLR fokozott génexpressziójára
SG11201901540UA (en) * 2016-06-22 2019-04-29 Univ Yale Mechanism based quality control for botanical medicine
EP3357504A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Funktionelles screening von antigenen polypeptiden verwendung zur identifizierung von antigenen zur anregung einer schützenden immunantwort und zur auswahl von antigenen mit optimaler schutzwirkung
EP3357506A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Mehrere malaria-prä-erythrozyten-antigene und deren verwendung bei der auslösung einer schützenden immunantwort in einem wirt
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
MX2020003954A (es) 2017-10-16 2020-10-05 Consorcio Centro De Investig Biomedica En Red M P Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa.
SG11202008400SA (en) 2018-04-11 2020-09-29 Rocket Pharmaceuticals Ltd Compositions and methods for stem cell transplant
JP7721436B2 (ja) 2018-04-12 2025-08-12 ウモジャ バイオファーマ インコーポレイテッド ウイルスベクター及びパッケージング細胞株
CA3096293A1 (en) 2018-04-27 2019-10-31 Rocket Pharmaceuticals, Ltd. Gene therapy for cns degeneration
US20210346306A1 (en) 2018-05-23 2021-11-11 Modernatx, Inc. Delivery of dna
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
US20220017920A1 (en) 2018-11-21 2022-01-20 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB2601618B (en) 2019-03-19 2024-11-06 Broad Inst Inc Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
EP4045663A2 (de) 2019-10-16 2022-08-24 Umoja Biopharma, Inc. Retroviraler vektor zur universellen rezeptortherapie
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
CN116323656A (zh) 2020-07-16 2023-06-23 优莫佳生物制药股份有限公司 门控衔接子靶向受体
AU2021310950A1 (en) 2020-07-24 2023-02-16 President And Fellows Of Harvard College Enhanced virus-like particles and methods of use thereof for delivery to cells
EP4192487A4 (de) 2020-08-07 2024-10-02 Spacecraft Seven, LLC Plakophilin-2 (pkp2) gentherapie unter verwendung eines aav vektors
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
EP3984548A1 (de) 2020-10-16 2022-04-20 Institut Pasteur Generation von lentiviralen vektoren, die es ermöglichen, antigene zum mhc-ii-weg zu leiten und cd4+- und cd8+-t-zellantworten als immunantwort in einem wirt zu induzieren
MX2023005876A (es) 2020-11-20 2023-07-20 Umoja Biopharma Inc Sistema de vector para administracion de multiples polinucleotidos y usos del mismo.
AU2022233021A1 (en) 2021-03-12 2023-09-21 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
CN119137261A (zh) 2021-12-17 2024-12-13 优莫佳生物制药股份有限公司 细胞毒性先天淋巴样细胞及其用途
KR20250011945A (ko) 2022-05-17 2025-01-22 우모자 바이오파마 인코포레이티드 바이러스 입자의 제조
CN119677772A (zh) 2022-06-10 2025-03-21 优莫佳生物制药股份有限公司 工程化干细胞及其用途
CN115358393B (zh) * 2022-09-13 2025-12-02 大连大学 一种基于相互作用力的dna三链体编码优化方法
WO2024084041A2 (en) 2022-10-21 2024-04-25 Institut Pasteur Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host
IL320495A (en) 2022-11-04 2025-06-01 Umoja Biopharma Inc Construction of polynucleotide vectors and related viral methods
WO2025129084A1 (en) 2023-12-13 2025-06-19 Umoja Biopharma, Inc. Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2247091A1 (en) * 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
WO1998046083A1 (en) 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en) * 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
AU784910B2 (en) 1999-10-12 2006-07-27 Centre National De La Recherche Scientifique Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
AU7921700A (en) 2001-04-23
EP1224314A2 (de) 2002-07-24
IL198076A (en) 2011-12-29
EP1792997A1 (de) 2007-06-06
AU2006233199B2 (en) 2009-07-23
AU2006233199A1 (en) 2006-11-23
US8512994B2 (en) 2013-08-20
US20120122204A1 (en) 2012-05-17
EP1792997B1 (de) 2011-11-02
CN1402793A (zh) 2003-03-12
CA2382832A1 (en) 2001-04-19
CN101363029B (zh) 2016-01-13
JP4436024B2 (ja) 2010-03-24
EP1224314B1 (de) 2007-01-17
IL148900A0 (en) 2002-09-12
ATE531808T1 (de) 2011-11-15
DE60033045D1 (de) 2007-03-08
US8093042B2 (en) 2012-01-10
CY1106513T1 (el) 2012-01-25
PT1224314E (pt) 2007-04-30
HK1050210B (en) 2007-08-24
US20180346928A1 (en) 2018-12-06
DK1224314T3 (da) 2007-05-21
AU784910B2 (en) 2006-07-27
CA2382832C (en) 2012-06-26
CN101363029A (zh) 2009-02-11
ES2377721T3 (es) 2012-03-30
US20070224679A1 (en) 2007-09-27
HK1109167A1 (en) 2008-05-30
JP2003511083A (ja) 2003-03-25
DE60033045T2 (de) 2007-11-08
HK1050210A1 (en) 2003-06-13
PT1792997E (pt) 2012-02-02
US8512993B2 (en) 2013-08-20
US10407695B2 (en) 2019-09-10
CY1112430T1 (el) 2015-12-09
US9238824B2 (en) 2016-01-19
WO2001027304A3 (en) 2001-11-29
US20150191745A1 (en) 2015-07-09
US20190119699A1 (en) 2019-04-25
CN100425702C (zh) 2008-10-15
IL148900A (en) 2009-11-18
US20120122963A1 (en) 2012-05-17
ES2280250T3 (es) 2007-09-16
US20150011006A1 (en) 2015-01-08
WO2001027304A2 (en) 2001-04-19
DK1792997T3 (da) 2012-01-30

Similar Documents

Publication Publication Date Title
DE60033045D1 (de) Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
JP2020100622A5 (de)
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
PT2302063T (pt) Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo
WO2002014358A3 (en) Novel secreted proteins and their uses
ATE198767T1 (de) Hantelförmige expressionskonstrukte für die gentherapie
CA2513072A1 (en) Cellular delivery and activation polypeptide-nucleic acid complexes
WO2000053788A3 (en) Compositions and methods for recombinant adeno-associated virus production
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
DE59911900D1 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
ATE475713T1 (de) Trans-lentivirales vektor system
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
NO885090D0 (no) Polypeptider.
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
ATE103934T1 (de) Impfstoff bestehend aus einem virusvektor und rekombinanten-dns, die das p25-protein vom aids- virus kodieren.
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2002016578A3 (en) Secreted proteins and methods of using same
WO2024150828A1 (ja) 遺伝子導入方法
RU2227161C1 (ru) Рекомбинантная плазмидная днк рвмс-qp120(a)m-1 для иммунизации против вируса иммунодефицита человека
JP2024099482A (ja) 分子導入方法、分子導入効率改善剤、使用、分子導入細胞、分子導入細胞の製造方法、及び分子導入装置
RU2346044C2 (ru) ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-gp140(A)-hum
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1224314

Country of ref document: EP